Steven Cohen’s Pacific Biosciences PACB Stock Holding History

Steven Cohen’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,000,000	Closed	-$1.83M	–	2412
2024 Q4	$1.83M	Buy	+1,000,000	New	+$1.95M	﹤0.01%	1280
2023 Q3	–	Sell	-200,000	Closed	-$2.66M	–	2772
2023 Q2	$2.66M	Buy	+200,000	New	+$2.43M	0.01%	980

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Steven Cohen's PACB Position: Q2 2026 in Review

Steven Cohen increased its Pacific Biosciences (PACB) stake by 1,576% in Q2 2026, buying an estimated $6.54M and bringing the position to 4,787,300 shares worth $8.04M. The position accounts for 0.01% of the portfolio, ranked #1422.

Steven Cohen first reported a position in PACB in Q2 2015 and has held it in 20 quarters since. The position peaked at $88.6M in Q2 2023. 222 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Steven Cohen held 4,787,300 shares of Pacific Biosciences worth $8.04M as of Q2 2026.
Steven Cohen bought 4,501,600 Pacific Biosciences shares in Q2 2026, an estimated $6.54M.
Pacific Biosciences made up 0.01% of Steven Cohen's portfolio in Q2 2026, its #1422 holding.
Steven Cohen first reported a position in Pacific Biosciences in Q2 2015 and has held it in 20 quarters since.
Steven Cohen's Pacific Biosciences position peaked at $88.6M in Q2 2023.
222 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.